

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM569975

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Bellicum Pharmaceuticals, Inc.		03/31/2020	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Oxford Finance LLC, as Collateral Agent		
<b>Street Address:</b>	133 North Fairfax Street		
<b>City:</b>	Alexandria		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22314		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86218763	GOCAR-T	
<b>Serial Number:</b>	85148750	CASPACE	
<b>Serial Number:</b>	85014486	BELLICUM	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8586385130		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	619-699-2700		
<b>Email:</b>	susan.reynolds@dlapiper.com		
<b>Correspondent Name:</b>	DLA Piper LLP (US)		
<b>Address Line 1:</b>	401 B Street, Suite 1700		
<b>Address Line 4:</b>	San Diego, CALIFORNIA 92101		
<b>NAME OF SUBMITTER:</b>	Matt Schwartz		
<b>SIGNATURE:</b>	/s/ Matt Schwartz		
<b>DATE SIGNED:</b>	04/01/2020		
<b>Total Attachments: 6</b>			
source=Oxford - Bellicum Phamaceuticals - IP Security Agreement (3.2020)#page1.tif			
source=Oxford - Bellicum Phamaceuticals - IP Security Agreement (3.2020)#page2.tif			
source=Oxford - Bellicum Phamaceuticals - IP Security Agreement (3.2020)#page3.tif			
source=Oxford - Bellicum Phamaceuticals - IP Security Agreement (3.2020)#page4.tif			

CH \$90.00 86218763

source=Oxford - Bellicum Phamaceuticals - IP Security Agreement (3.2020)#page5.tif  
source=Oxford - Bellicum Phamaceuticals - IP Security Agreement (3.2020)#page6.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the March 31, 2020 by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the "Lenders") described in the Loan Agreement (in such capacity, the "Collateral Agent") and BELLICUM PHARMACEUTICALS, INC., a Delaware corporation with offices located at 2130 West Holcombe Boulevard, Suite 800, Houston, Texas 77030 ("Grantor").

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the December 21, 2017 (as the same may be amended, modified or supplemented from time to time, including but not limited to that certain First Amendment to Loan and Security Agreement dated as of December 24, 2019, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

2130 West Holcombe Boulevard, Suite 800  
Houston, Texas 77030

BELLICUM PHARMACEUTICALS, INC.

DocuSigned by:  
  
By: \_\_\_\_\_  
.....F6D9DF26BC6E4E0.....

Title: Chief Financial Officer

COLLATERAL AGENT:

OXFORD FINANCE LLC

Address of Lender:

133 North Fairfax Street  
Alexandria, Virginia 22314  
Attn: Legal Department

By: \_\_\_\_\_

Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

BELLICUM PHARMACEUTICALS, INC.

2130 West Holcombe Boulevard, Suite 800  
Houston, Texas 77030

By: \_\_\_\_\_


Title: \_\_\_\_\_

Address of Lender:

COLLATERAL AGENT:

OXFORD FINANCE LLC

133 North Fairfax Street  
Alexandria, Virginia 22314  
Attn: Legal Department

By:  \_\_\_\_\_  
Colette H. Featherly

Title: \_\_\_\_\_  
Senior Vice President

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

EXHIBIT B

Patents

<u>Description</u>	<u>Patent/App. No.</u>	<u>Issue/File Date</u>
Methods for inducing partial apoptosis using caspase polypeptides	10525110	1/7/20
Modified caspase polypeptides and uses thereof	9434935	9/6/16
Methods for inducing partial apoptosis using caspase polypeptides	9913882	3/13/18
Modified caspase polypeptides and uses thereof	9932572	4/3/18
Methods for controlling T cell proliferation	9944690	4/17/18
Methods for activating T cells using an inducible chimeric polypeptide	14622018	2/13/15
Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides	16788062	2/11/20
Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides	14842710	9/1/15
Methods for controlled elimination of therapeutic cells	14968737	12/14/15
Methods for controlled activation or elimination of therapeutic cells	14968853	12/14/15
Dual controls for therapeutic cell activation or elimination	15377776	12/13/16
Modified caspase polypeptides and uses thereof	15901556	2/21/18
Methods for controlling T cell proliferation	15910380	3/2/18
Methods for inducing partial apoptosis using caspase polypeptides	16734104	1/3/20
Methods to augment or alter signal transduction	16611772	5/8/18

EXHIBIT C

Trademarks

<u>Description</u>	<u>Serial No.</u>	<u>File Date</u>
GOCAR-T	86218763	3/12/14
CASPACIDE	85148750	10/8/10
BELLICUM	85014486	4/15/10